Track Genmab A/S — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Genmab A/S GMAB · Stock Open Genmab A/S in new tab

51.37 USD
P/E
46.21
EPS
1.17
P/B
5.40
ROE
12.07
Beta
0.52
Target Price
65.11 USD
Genmab A/S logo

Genmab A/S

🧾 Earnings Recap – Q3 2026

The stock fell 2.7% after earnings, a roughly flat reaction under the stated threshold. Revenue rose 22% and adjusted operating profit 9%, while the call also highlighted positive phase III readouts and commercial growth.

  • Total revenue increased 22% and adjusted operating profit increased 9%, according to management.
  • EPKINLY sales were $491 million for the first nine months, up 47% year over year.
  • TIVDAK sales were $131 million for the first nine months, up 9% year over year.
  • Genmab reported positive phase III results for EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer.
  • The next petosemtamab milestone, the LiGeR-HN2 trial in the second- and third-line setting, is expected in the first quarter of 2027.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 16, 2027
P/E46.21
EPS1.17
Book Value10.01
Price to Book5.40
Debt/Equity82.08
% Insiders0.019%
Growth
Revenue Growth0.16%
Earnings Growth-0.15%
Estimates
Forward P/E34.22
Forward EPS1.58
Target Mean Price65.11

DCF valuation

Model fair value for Genmab A/S (GMAB)
Result
Sign in to run the valuation for GMAB.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 65.11 USD (low 48.00, high 80.00) · as of 11 Nov 2026
Low 48.00
Mean 65.11
High 80.00
Price 51.37
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Genmab A/S Logo Genmab A/S Analysis (GMAB)

Denmark Health Care Official Website Stock

Is Genmab A/S a good investment? Genmab A/S (GMAB) is currently trading at 51.37 USD. Market analysts have a consensus price target of 65.11 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 46.21. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Genmab A/S is expected to release its next earnings report on Feb. 16, 2027. The market consensus estimate for Forward EPS is 1.58.

Investor FAQ

Does Genmab A/S pay a dividend?

No, it does not currently pay a dividend.

What asset class is Genmab A/S?

Genmab A/S is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 16, 2027. The company currently has a trailing EPS of 1.17.

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Exchange Ticker
NMS (United States) GMAB
US3723032062
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 1, 2018 5:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion